REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress

Impact · against what's priced in

The recent surge in REPL shares reflects the market finally paying for the FDA approval and commercial launch of Tudriqev, which the price had previously declined. The transition to a commercial-stage company and better-than-expected earnings now shift the valuation focus toward revenue growth and cash runway.

REPL+0.80

Challenges what's priced in

The price assumes

A successful FDA approval of RP1 by the August 2 decision date